Research Funding

DoD Preannouncement for Peer Reviewed Medical Research

The Defense Health Program Department of Defense Peer Reviewed Medical Research Program

Funding Opportunities for Fiscal Year 2016

The Fiscal Year 2016 (FY16) Defense Appropriations Act provides $278.7 million to the Department of Defense Peer Reviewed Medical Research Program (PRMRP). The vision of the PRMRP is to improve the health and well-being of all military Service members, Veterans, and beneficiaries. The PRMRP challenges the scientific and clinical communities to address one of the FY16 congressionally directed topic areas with original ideas that foster new directions in basic science and translational research; novel product development leading to improved therapeutic or diagnostic tools; synergistic, multidisciplinary research programs; or clinical trials that address an immediate clinical need.

The PRMRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY16 PRMRP Program Announcements and General Application Instructions are anticipated to be posted on Grants.gov by late March 2016. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.

Congressionally Directed Topic Areas. The FY16 PRMRP will solicit research applications for the following 39 topics areas:

  • Acute Lung Injury
  • Antimicrobial Resistance
  • Chronic Migraine and Post-Traumatic Headache
  • Congenital Heart Disease
  • Constrictive Bronchiolitis
  • Diabetes
  • Dystonia
  • Emerging Infectious Diseases
  • Focal Segmental Glomerulosclerosis
  • Fragile X Syndrome
  • Hepatitis B
  • Hereditary Angioedema
  • Hydrocephalus
  • Inflammatory Bowel Disease
  • Influenza
  • Integrative Medicine
  • Interstitial Cystitis
  • Lupus
  • Malaria
  • Metals Toxicology
  • Mitochondrial Disease
  • Nanomaterials for Bone Regeneration
  • Nonopioid Pain Management
  • Pancreatitis
  • Pathogen-Inactivated Dried Plasma
  • Polycystic Kidney Disease
  • Post-Traumatic Osteoarthritis
  • Psychotropic Medications
  • Pulmonary Fibrosis
  • Respiratory Health
  • Rett Syndrome
  • Rheumatoid Arthritis
  • Scleroderma
  • Sleep Disorders
  • Tinnitus
  • Tuberculosis
  • Vaccine Development for Infectious Disease
  • Vascular Malformations
  • Women’s Heart Disease

Military Relevance:Relevance to the healthcare needs of the military Service members, Veterans, and beneficiaries is a key feature of each FY16 PRMRP award mechanism.

Clinical Trial Award

Assistant Professor level or above (or equivalent)

Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area(s) of interest.

Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.

Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration before the PRMRP Grants.gov application submission deadline.

Preproposal submission is required; application submission is by invitation only

Funding limit not defined; requested funding must be appropriate for the scope of work proposed

Maximum period of performance is 5 years

Discovery Award

All Investigators

Supports the exploration of a highly innovative new concept or untested theory.

Not intended to support the logical progression of an already established line of questioning.

Clinical trials will not be funded.

Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organization(s)

Maximum of $200,000 for direct costs (plus indirect costs)

Maximum period of performance is 18 months

Focused Program Award

Full Professor level or above (or equivalent)

Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal in one of the topic areas listed directly above. Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications. Projects may range from exploratory/ hypothesis-developing through small-scale clinical trials that together will address the overarching goal/question. Research team of highly qualified, multidisciplinary project leaders should be led by a PI with demonstrated success in directing large, focused projects.

Preproposal submission is required; application submission is by invitation only.

Maximum of $10 million for total costs (includes direct and indirect costs)

Maximum period of performance is 5 years

Investigator-Initiated Research Award

Assistant Professor level or above (or equivalent)

Supports research that will make an original and important contribution to the field of research or patient care in the topic area(s) of interest.

Partnering PI Option available.

Clinical trials will not be funded.

Preproposal submission is required; application submission is by invitation only.

Maximum of $1.2 million for direct costs (plus indirect costs)

Maximum of $1.5 million for direct costs (plus indirect costs) for applications including a Partnering PI Option

Maximum period of performance is 3 years

Technology/ Therapeutic Development Award

Assistant Professor level or above (or equivalent)

Supports the development of diagnostics or therapies that have the potential to make a strong impact on patient care in the topic area(s) of interest.

Product-oriented (e.g., device, drug, clinical guidelines).

Clinical trials will not be funded.

Preproposal submission is required; application submission is by invitation only

Maximum of $3.0 million for direct costs (plus indirect costs)

Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government’s single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. Requests for email notification of the Program Announcements’ release may be sent to help@ebrap.org. For more information about the PRMRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs

301-619-9783

mailto:usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

Classification: UNCLASSIFIED Caveats: NONE

FY15 Extremity Regeneration Intervention

SUBMISSION AND REVIEW DATES AND TIMES

Pre-Application Deadline: 5:00 p.m. Eastern time (ET), December 15, 2015

Application Submission Deadline: 11:59 p.m. ET, December 22, 2015

Independent extramural investigators at all academic levels (or equivalent)

  • Supports Phase I, II, or pivotal clinical trial phase development projects focused on extremity regeneration.
  • The focus is on bone and soft tissue reconstruction, limb and tissue salvage technologies, and regenerative medicine technologies for the treatment of trauma-induced damage.
  • Must specifically address one or both of the FY15 Focus Areas.
  • Funding from this award mechanism must support a clinical trial and development-related efforts and may not be used for preclinical research studies.
  • The maximum period of performance is 4 years.
  • The maximum allowable funding (total costs) for the entire period of performance is $4.9 Million.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism can also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government’s single-entry portal, Grants.gov. Requests for email notification of the Program Announcements release may be sent to help@ebrap.org. For more information about the PRORP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

The JPC-8/CRMRP is one of six major DHP core research program areas within the DHP DHA RDA Directorate and is administered with oversight from JPC-8, which consists of Department of Defense (DoD) and non-DoD medical and military technical experts relevant to the program area. The JPC-8/CRMRP focuses on innovations to reconstruct, rehabilitate, and provide definitive care for injured Service members. The ultimate goal is to return the Service members to duty and restore their quality of life. Innovations developed from JPC-8/CRMRP-supported research efforts are expected to improve restorative treatments and rehabilitative care to maximize function for return to duty (RTD) or civilian life. The interest is in medical technologies (drugs, biologics, and devices) and treatment/rehabilitation strategies (methods, guidelines, standards, and information) that will significantly improve the medical care provided to our wounded Service members within the DoD health care system. Implementation of these technologies and strategies should improve the rate of RTD of Service members, the time to RTD, clinical outcome measures, and quality of life, as well as reduce the hospital stay lengths, clinical workload (patient encounters, treatments, etc.), and initial and long-term costs associated with restorative and rehabilitative or acute care.

Point of Contact:

CDMRP Help Desk 301-682-5507

help@eBrap.org

FY15 Peer Reviewed Cancer Research Program RFA

The FY15 Defense Appropriations Act provides $50 million (M) to the Department of Defense Peer Reviewed Cancer Research Program (PRCRP) to support innovative, high-impact cancer research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate manages and executes the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The executing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

FY15 PRCRP Program Announcement and General Application Instructions for the following award mechanism are posted on the Grants.gov website.
Congressionally Directed Topic Areas: To be considered for funding, applications for the FY15 PRCRP must address at least one of the Topic Areas as directed by Congress. Research applications in the areas of breast, prostate, lung (excluding mesothelioma), or ovarian cancer will not be accepted. The FY15 PRCRP Topic Areas are listed below:

  • Colorectal cancer
  • Genetic cancer
  • Kidney cancer
  • Listeria vaccine for cancer
  • Liver cancer (New for FY15)
  • Melanoma and other skin cancers
  • Mesothelioma
  • Myeloproliferative disorders
  • Neuroblastoma
  • Pancreatic cancer
  • Stomach cancer (New for FY15)

To address the cancer health needs of both deployed and non-deployed personnel, their dependents, retirees, and Veterans, the FY15 PRCRP encourages studies that are responsive to the FY15 Military Relevance Focus Areas listed below:

  • Militarily relevant risk factors associated with cancer (e.g., ionizing radiation, chemicals, infectious agents, and environmental carcinogens).
  • Gaps in cancer prevention, screening, early detection, diagnosis, treatment, and/or survivorship that may affect the general population but have a particularly profound impact on the health and well-being of military members, Veterans, and their beneficiaries.

Horizon Award – Letter of Intent due August 11, 2015

PI:  Both pre-doctoral candidates and postdoctoral fellows are eligible.

Mentor: The Mentor must be an experienced cancer researcher as demonstrated by a strong record of funding and publications. In addition, the Mentor must demonstrate a commitment to advancing the PI’s career in cancer research.

The PI and the Mentor must be at the same organization

  • Letter of Intent is required.
  • Supports junior level scientists to conduct impactful research with the mentorship of an experienced cancer researcher (i.e., Mentor)
  • Challenges junior scientists to develop and implement research in the cancer field
  • Emphasis on discovery
  • Must address at least one of the FY15 PRCRP Topic Areas
  • Encouraged to address at least one of the FY15 PRCRP Military Relevance Focus Areas
  • Preliminary data are not required

Clinical trials are not allowed

    • Maximum funding for the entire period of performance is $75,000 for direct costs (plus indirect costs)

Maximum period of performance is 1 year

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that are available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government’s single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. Requests for email notification of the Program Announcements release may be sent to help@ebrap.org. For more information about the PRCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:
CDMRP Help Desk 301-6682-5507 help@rebrap.org